Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rajeshwar P Mookerjee

Showing results (91-100 of 120) with videos related to

Pageof 12
Sort By:
Cell Death & Disease|December 18, 2021
The role of RIPK1 mediated cell death in acute on chronic liver failureTakayuki Kondo, Stewart Macdonald, Cornelius Engelmann, et al.
Journal of Hepatology|December 3, 2014
Immunomodulatory and antioxidant function of albumin stabilises the endothelium and improves survival in a rodent model of chronic liver failureRita Garcia-Martinez, Fausto Andreola, Gautam Mehta, et al.
BMJ Open|July 7, 2025
Prospective multicentre randomised controlled trial to assess the clinical effectiveness of the novel CirrhoCare digital therapeutic management system: a study protocolOlivia Greenham, Kohilan Gananandan, Anu Balaji, et al.
Journal of Hepatology|January 24, 2012
Prevention of acute kidney injury in a rodent model of cirrhosis following selective gut decontamination is associated with reduced renal TLR4 expressionNaina Shah, Dipok Dhar, Fatma El Zahraa Mohammed, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|January 22, 2013
A reproducible, clinically relevant, intensively managed, pig model of acute liver failure for testing of therapies aimed to prolong survivalKarla C L Lee, Carolina Palacios Jimenez, Hatim Alibhai, et al.
Hepatology (Baltimore, Md.)|January 9, 2021
The Use of Rifaximin in Patients With CirrhosisPaolo Caraceni, Victor Vargas, Elsa Solà, et al.
European Journal of Clinical Pharmacology|November 22, 2011
Hemodynamics and pharmacokinetics of tezosentan, a dual endothelin receptor antagonist, in patients with cirrhosisDidier Lebrec, Jaime Bosch, Rajiv Jalan, et al.
Journal of Hepatology|August 14, 2025
Identification and validation of RIPK3 as a novel biomarker to predict outcomes in patients with acutely decompensated cirrhosisNipun Verma, Pratibha Garg, Parminder Kaur, et al.
Journal of Hepatology|July 8, 2018
Urea cycle dysregulation in non-alcoholic fatty liver diseaseFrancesco De Chiara, Sara Heebøll, Giusi Marrone, et al.
JHEP Reports : Innovation in Hepatology|March 1, 2024
AlcoChange: A digital therapeutic for patients with alcohol-related liver diseaseGautam Mehta, Su Lin, Aida Nadar, et al.
Pageof 12

Showing results (91-100 of 120) with videos related to

Sort By:
Pageof 12
Cell Death & Disease|December 18, 2021
The role of RIPK1 mediated cell death in acute on chronic liver failureTakayuki Kondo, Stewart Macdonald, Cornelius Engelmann, et al.
Journal of Hepatology|December 3, 2014
Immunomodulatory and antioxidant function of albumin stabilises the endothelium and improves survival in a rodent model of chronic liver failureRita Garcia-Martinez, Fausto Andreola, Gautam Mehta, et al.
BMJ Open|July 7, 2025
Prospective multicentre randomised controlled trial to assess the clinical effectiveness of the novel CirrhoCare digital therapeutic management system: a study protocolOlivia Greenham, Kohilan Gananandan, Anu Balaji, et al.
Journal of Hepatology|January 24, 2012
Prevention of acute kidney injury in a rodent model of cirrhosis following selective gut decontamination is associated with reduced renal TLR4 expressionNaina Shah, Dipok Dhar, Fatma El Zahraa Mohammed, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|January 22, 2013
A reproducible, clinically relevant, intensively managed, pig model of acute liver failure for testing of therapies aimed to prolong survivalKarla C L Lee, Carolina Palacios Jimenez, Hatim Alibhai, et al.
Hepatology (Baltimore, Md.)|January 9, 2021
The Use of Rifaximin in Patients With CirrhosisPaolo Caraceni, Victor Vargas, Elsa Solà, et al.
European Journal of Clinical Pharmacology|November 22, 2011
Hemodynamics and pharmacokinetics of tezosentan, a dual endothelin receptor antagonist, in patients with cirrhosisDidier Lebrec, Jaime Bosch, Rajiv Jalan, et al.
Journal of Hepatology|August 14, 2025
Identification and validation of RIPK3 as a novel biomarker to predict outcomes in patients with acutely decompensated cirrhosisNipun Verma, Pratibha Garg, Parminder Kaur, et al.
Journal of Hepatology|July 8, 2018
Urea cycle dysregulation in non-alcoholic fatty liver diseaseFrancesco De Chiara, Sara Heebøll, Giusi Marrone, et al.
JHEP Reports : Innovation in Hepatology|March 1, 2024
AlcoChange: A digital therapeutic for patients with alcohol-related liver diseaseGautam Mehta, Su Lin, Aida Nadar, et al.
Pageof 12